Skip to content
Peptide research

CJC-1295

Also known as Modified GRF(1-29) · Mod GRF
Category
Growth Hormone
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A synthetic growth hormone-releasing hormone analog, often built with a Drug Affinity Complex (DAC) that extends its half-life to days, marketed for body composition, sleep, recovery, and bone. It reliably raises growth hormone, but the clinical benefits remain speculative in humans. Safety is the gap: long-term data is thin, the long-acting form is hard to stop, and it can cause water retention and joint pain. Not an approved US drug and banned by WADA.

Read Full record

Studied uses & evidence

Studied uses(7)

  • Sustained GH elevation

    High

    Human RCT showed GH rising 2 to 10x for 6+ days per injection, accumulating with repeat dosing.

  • Preserved GH pulsatility

    Medium

    Human trial data indicate the natural GH pulse pattern is maintained, unlike exogenous GH.

  • Improved body composition

    Speculative

    Preliminary, based on the GH/IGF-1 rise promoting lipolysis and lean mass; no completed outcome trial.

Evidence limits

Evidence Level
Phase 2 (Discontinued)

Foundational 2006 Teichman et al. RCT demonstrated dose-dependent GH/IGF-1 elevation. Ionescu 2006 confirmed preserved pulsatility. Development halted after Phase II death (attributed to pre-existing CAD). No further pharma-sponsored trials.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Pituitary tumors

    Absolute

    Directly stimulates pituitary GHRH receptors.

  • Active cancer

    High

    Sustained GH elevation via GHRH mimicry may promote tumor growth.

  • Diabetic retinopathy

    High

    GH/IGF-1 axis activation can accelerate retinal damage.

General cautions

  • Pregnancy

    Absolute

    No safety data.

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • One Phase II death was reported; coronary artery disease was considered the likely explanation, with drug causality unresolved.

    Low
  • Long-term safety data beyond a few months is lacking

    High
  • DAC version half-life 6-8 days cannot quickly discontinue if adverse reaction

    Moderate
  • Water retention (hands, feet, face)

    Moderate
  • Potential GH-related side effects: joint pain, carpal tunnel, insulin resistance

    Moderate
  • WADA banned

    High
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.